• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

含芳杂环取代的马蹄金素衍生物的设计、合成及抗乙肝病毒活性

邱净英, 胡占兴, 徐必学, 潘卫东, 黄正明, 刘昌孝, 梁光义

邱净英, 胡占兴, 徐必学, 潘卫东, 黄正明, 刘昌孝, 梁光义. 含芳杂环取代的马蹄金素衍生物的设计、合成及抗乙肝病毒活性[J]. 中国药科大学学报, 2015, 46(6): 641-646. DOI: 10.11665/j.issn.1000-5048.20150601
引用本文: 邱净英, 胡占兴, 徐必学, 潘卫东, 黄正明, 刘昌孝, 梁光义. 含芳杂环取代的马蹄金素衍生物的设计、合成及抗乙肝病毒活性[J]. 中国药科大学学报, 2015, 46(6): 641-646. DOI: 10.11665/j.issn.1000-5048.20150601
QIU Jingying, HU Zhanxing, XU Bixue, PAN Weidong, HUANG Zhengming, LIU Changxiao, LIANG Guangyi. Synthesis and anti-HBV activity evaluation of Matijin-Su derivatives with aromatic heterocycles[J]. Journal of China Pharmaceutical University, 2015, 46(6): 641-646. DOI: 10.11665/j.issn.1000-5048.20150601
Citation: QIU Jingying, HU Zhanxing, XU Bixue, PAN Weidong, HUANG Zhengming, LIU Changxiao, LIANG Guangyi. Synthesis and anti-HBV activity evaluation of Matijin-Su derivatives with aromatic heterocycles[J]. Journal of China Pharmaceutical University, 2015, 46(6): 641-646. DOI: 10.11665/j.issn.1000-5048.20150601

含芳杂环取代的马蹄金素衍生物的设计、合成及抗乙肝病毒活性

基金项目: 国家自然科学基金资助项目(No.81360472);江苏省自然科学基金资助项目(No.BK20140223)

Synthesis and anti-HBV activity evaluation of Matijin-Su derivatives with aromatic heterocycles

  • 摘要: 以马蹄金素(MTS)为先导化合物,设计、合成了11个新的含芳杂环取代的马蹄金素衍生物,其结构经NMR、ESI-MS确认。采用HepG2 2.2.15细胞为乙肝病毒载体,评价目标化合物的抗HBV活性。结果表明,化合物 7a [IC50=2.94 μmol/L,选择指数(SI)=146.39]和 9a (IC50=2.21 μmol/L,SI>;250)对HBV DNA复制的抑制活性高于先导化合物MTS(IC50=11.16 μmol/L,SI=10.78),且具有更高的SI,提示该化合物在治疗HBV感染时具有更高的安全性,具有潜在的研究开发价值。
    Abstract: Hepatitis B virus(HBV)-infected hepatitis is one of the most common infectious disease worldwide. To find novel effective anti-HBV agents, a series of Matijin-Su(MTS)derivatives with aromatic heterocycles were synthesized and evaluated for their anti- HBV activities in HepG2 2. 2. 15 cells. Among them, compounds 7a( IC50=2. 94 μmol/L)and 9a( IC50=2. 21 μmol/L)exhibited more potent inhibitory activity against the replication of HBV DNA in HepG2 2. 2. 15 cells than that of lead compound MTS(IC50=11. 16 μmol/L). Notably, both 7a and 9a displayed a high selective index(SI)of 146. 39 and > 250, respectively, which were also much higher than that of MTS(SI=10. 78). Therefore, compounds 7a and 9a may be promising anti-HBV agents with safety profile for HBV infection.
  • [1] Zhang YY,Hu KQ.Rethinking the pathogenesis of hepatitis B virus(HBV)infection[J].J Med Virol,2015,87(12):1989-1999.
    [2] Qiu LP,Chen L,Chen KP.Antihepatitis B therapy:a review of current medications and novel small molecule inhibitors[J].Fund Clin Pharmacol,2014,28(4):364-381.
    [3] Watashi K,Urban S,Li W,et al.NTCP and beyond:opening the door to unveil hepatitis B virus entry[J].Int J Mol Sci,2014,15(2):2892-2905.
    [4] Kang L,Pan JQ,Wu J,et al.Anti-HBV drugs:progress,unmet needs,and new hope[J].Viruses-Basel,2015,7(9):4960-4977.
    [5] You CR, Lee SW, Jang JW, et al. Update on hepatitis B virus infection[J].World J Gastroenterol,2014,20(37):13293-13305.
    [6] Bhattacharya D,Thio CL.Review of hepatitis B therapeutics[J].Clin Infect Dis,2010,51(10):1201-1208.
    [7] Qiu JY,Xu BX,Huang ZM,et al.Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents[J].Bioorg Med Chem,2011,19(18):5352-5360.
    [8] Xu BX,Huang ZM,Liu CX,et al.Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives[J].Bioorg Med Chem,2009,17(8):3118-3125.
    [9] Qiu JY,Huang ZM,Pan WD,et al.Synthesis and anti-hepatitis B virus activities of Matjin-Su derivatives[J].J China Pharm Univ(中国药科大学学报),2012,43(5):390-394.
计量
  • 文章访问数:  1152
  • HTML全文浏览量:  1
  • PDF下载量:  1947
  • 被引次数: 0
出版历程
  • 刊出日期:  2015-12-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭